Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Radiofrequency Ablation Durable After 2 Years, Compares Favorably With Endoscopic Resection For Advanced Disease, Reduces Risk For Cancer Progression
Results from a number of clinical trials were presented during the Digestive Disease Week (DDW) in Chicago this week, revealing new outcomes data related to endoscopic radiofrequency ablation using the HALO ablation system for eradicating a pre-cancerous esophageal condition known as Barrett"s esophagus. Among them, reports included durability outcomes from a randomized sham-controlled trial, safety and efficacy outcomes from a large U.S. registry of 429 patients, a randomized trial comparing ablation to endoscopic resection, and the largest European series to date in patients with high-grade dysplasia and early cancer.
generic viagra online
News From The June Issue Of CHEST
PULMONARY HYPERTENSION: A CASE OF MISTAKEN IDENTITY?
News of the day
FDA Advisory Committee Votes In Favor Of SAPHRIS(R) (asenapine) For Acute Bipolar I Disorder And Acute Schizophrenia
Schering-Plough Corporation (NYSE: SGP) announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted unanimously in favor of SAPHRIS(R) (asenapine) sublingual tablets as effective and safe for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults and in favor of use in acute treatment of schizophrenia in adults. If approved by FDA, SAPHRIS would be the first psychotropic drug to be approved initially for both of these indications.
Health Insurance

Inconclusive Research Links Glargine Insulin (Lantus) With Cancer

Diabetes UK has today cautioned that research claiming there is a link between certain insulins and some cancers is "inconclusive". Results of four studies looking at the risk of cancer largely in people with Type 2 diabetes treated with insulin, particularly glargine insulin (Lantus), were published in Diabetologia - the Journal of the European Association for the Study of Diabetes - last week. The studies were based in Germany, Sweden, Scotland and the UK. The data of around 300,000 people treated with insulin was reviewed in the studies, of which 34,392 were taking glargine insulin (Lantus) alone. The German study suggested there may be a small increased risk of cancer in those taking glargine as their only insulin; with the strongest link seeming to be with breast cancer in older people. This small increase in risk appeared in two of the other three studies and seemed to be more so in people on high doses. Sir Professor George Alberti, Chairman of Diabetes UK, said: "It should be stated firmly that the evidence in these studies is not conclusive and that there are limitations with the research. "People with diabetes who are using glargine insulin should continue to take their medication as prescribed. You will become very ill if you stop taking your insulin. If you are concerned about these findings then you should speak to your healthcare team about your anxieties before discontinuing any treatment." Diabetes UK


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009